Market capitalization | $10.92b |
Enterprise Value | $12.76b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.88 |
P/S ratio (TTM) P/S ratio | 4.18 |
P/B ratio (TTM) P/B ratio | 3.42 |
Revenue growth (TTM) Revenue growth | 13.54% |
Revenue (TTM) Revenue | $2.61b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
24 Analysts have issued a Exact Sciences Corporation forecast:
24 Analysts have issued a Exact Sciences Corporation forecast:
Jun '24 |
+/-
%
|
||
Revenue | 2,612 2,612 |
14%
14%
|
|
Gross Profit | 1,819 1,819 |
14%
14%
|
|
EBITDA | -61 -61 |
64%
64%
|
EBIT (Operating Income) EBIT | -281 -281 |
28%
28%
|
Net Profit | -175 -175 |
59%
59%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.
Head office | United States |
CEO | Kevin Conroy |
Employees | 6,600 |
Founded | 1995 |
Website | www.exactsciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.